Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Oncovin, Vincasar PFS, Marqibo
Vincristine is a vinca alkaloid antineoplastic agent used in combination chemotherapy regimens to treat various types of cancer. It works by interfering with cell division, specifically by binding to tubulin, a protein essential for microtubule formation within cells. Microtubules are crucial for cell division and other cellular processes. By disrupting microtubule formation, vincristine inhibits cell division and leads to cell death, primarily in rapidly dividing cancer cells.
Used to treat various cancers, including leukemia, lymphoma, neuroblastoma, rhabdomyosarcoma, Wilms' tumor, and others as part of combination chemotherapy.
For intravenous use only; fatal if given intrathecally. Extravasation may result in severe local tissue necrosis.
Outcome:
Increased risk of vincristine toxicity
Mechanism:
Inhibition of vincristine metabolism
Outcome:
Increased vincristine bioavailability
Mechanism:
Altered drug metabolism
Outcome:
May increase vincristine levels
Mechanism:
Competition for protein binding sites
Most likely new formulation: liposomal vincristine for improved delivery and reduced toxicity (Year: 2025+, 70% confidence)
Based on historical data and ongoing research, vincristine is expected to maintain its current regulatory status for the foreseeable future.
Antineoplastic, Vinca Alkaloid, Mitotic Inhibitor
Vinca Alkaloid